What is avb drug

Ultimately, patients who relapse become platinum-resistant and the identification of effective and tolerable treatment options is considered a high unmet clinical need. We are focused on addressing the high unmet need in this patient population and successfully completed a Phase 1b trial of AVB in patients with platinum resistant ovarian cancer. Kidney cancer is a leading cause of cancer-related deaths in the United States and is among the 10 most common cancers in both men and women.

It is estimated that there will be approximately 76, new cases of kidney cancer and 13, people will die from this disease in the United States in Pancreatic cancer is the seventh leading cause of cancer death worldwide. There were approximately , new cases of pancreatic cancer and , deaths from the disease worldwide in It is estimated that there will be approximately 60, new cases of pancreatic cancer and 48, deaths from the disease in the U.

Pancreatic adenocarcinoma is the most common type of pancreatic cancer, and there is a clear, high, unmet medical need to improve patient survival with new effective treatments that are safe and well-tolerated. Pancreatic cancer is projected to become the third leading cause of cancer death worldwide by and the second leading cause of cancer death in the U. Phase 2 Phase 2a Phase 2b.

Available archived tumor tissue or if archived tissue is not available, a fresh tumor biopsy. Received at least 1 but not more than 4 prior therapy regimens. At least 28 days between termination of prior anticancer or hormonal therapy and first administration of AVB-S Full recovery from all treatment-related toxicities to Grade 1 or less, except alopecia. Primary platinum-refractory disease defined as progression during or within 4 weeks after completion of the first platinum regimen Is being treated with concurrent anticancer therapy or other interventional treatments administered for their underlying ovarian cancer.

Received prior therapy with PAC in the platinum-resistant recurrent setting Evidence of clinically significant third spacing e. Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials. Layout table for location contacts Contact: Aravive Clinical Trials clinicaltrials aravive. Sudarshan K. Sharma, Ltd. More Information. Layout table for additonal information Responsible Party: Aravive, Inc. Ovarian cancer Platinum resistant Recurrent ovarian cancer High-grade serous adenocarcinoma. National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

Platinum-resistant Ovarian Cancer. AVB-S Avelumab. AVB-S Cabozantinib. AVB-S Durvalumab. AVB-S Paclitaxel.